Follow the people · Insider
Johannes Jacob Pieter Kastelein
Johannes Jacob Pieter Kastelein files insider transactions with the SEC as a chief scientific officer of NewAmsterdam Pharma Co (NAMS). We hold 6 disclosed purchases and sales filed since 3 January 2024, 1 of them in the last 90 days.
- Files forNAMS
- Disclosed buys and sells6 in all, 1 in the last 90 days
- Last disclosure25 August 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 1 January 2024 — 24 August 2026Chief Scientific Officer · NewAmsterdam Pharma Co (NAMS)47 Form 4 lines · source: SEC Form 4
Everything they disclosed
47 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 125,000 shares of NewAmsterdam Pharma CoSEC Form 425 August 2026Ordinary Shares · traded 24 August 2026 · filed 25 August 2026
- ▼ sold on the open market 125,000 shares of NewAmsterdam Pharma CoSEC Form 425 August 2026Ordinary Shares · traded 24 August 2026 · filed 25 August 2026
- exercised options over 125,000 shares of NewAmsterdam Pharma Co (a derivative holding)SEC Form 425 August 2026Option (right to buy) · traded 24 August 2026 · filed 25 August 2026
- exercised options over 104,467 shares of NewAmsterdam Pharma CoSEC Form 49 March 2026Ordinary Shares · traded 5 March 2026 · filed 9 March 2026
- ▼ sold on the open market 104,467 shares of NewAmsterdam Pharma CoSEC Form 49 March 2026Ordinary Shares · traded 5 March 2026 · filed 9 March 2026
- exercised options over 94,124 shares of NewAmsterdam Pharma CoSEC Form 49 March 2026Ordinary Shares · traded 6 March 2026 · filed 9 March 2026
- exercised options over 104,467 shares of NewAmsterdam Pharma Co (a derivative holding)SEC Form 49 March 2026Option (right to buy) · traded 5 March 2026 · filed 9 March 2026
- exercised options over 94,124 shares of NewAmsterdam Pharma Co (a derivative holding)SEC Form 49 March 2026Option (right to buy) · traded 6 March 2026 · filed 9 March 2026
- exercised options over 101,409 shares of NewAmsterdam Pharma Co (a derivative holding)SEC Form 49 March 2026Option (right to buy) · traded 9 March 2026 · filed 9 March 2026
- ▼ sold on the open market 94,124 shares of NewAmsterdam Pharma CoSEC Form 49 March 2026Ordinary Shares · traded 6 March 2026 · filed 9 March 2026
- exercised options over 101,409 shares of NewAmsterdam Pharma CoSEC Form 49 March 2026Ordinary Shares · traded 9 March 2026 · filed 9 March 2026
- ▼ sold on the open market 101,409 shares of NewAmsterdam Pharma CoSEC Form 49 March 2026Ordinary Shares · traded 9 March 2026 · filed 9 March 2026
- exercised options over 104,467 shares of NewAmsterdam Pharma Co (a derivative holding)SEC Form 49 March 2026Option (right to buy) · traded 5 March 2026 · filed 9 March 2026
- exercised options over 94,124 shares of NewAmsterdam Pharma Co (a derivative holding)SEC Form 49 March 2026Option (right to buy) · traded 6 March 2026 · filed 9 March 2026
- exercised options over 104,467 shares of NewAmsterdam Pharma CoSEC Form 49 March 2026Ordinary Shares · traded 5 March 2026 · filed 9 March 2026
- ▼ sold on the open market 104,467 shares of NewAmsterdam Pharma CoSEC Form 49 March 2026Ordinary Shares · traded 5 March 2026 · filed 9 March 2026
- exercised options over 94,124 shares of NewAmsterdam Pharma CoSEC Form 49 March 2026Ordinary Shares · traded 6 March 2026 · filed 9 March 2026
- ▼ sold on the open market 94,124 shares of NewAmsterdam Pharma CoSEC Form 49 March 2026Ordinary Shares · traded 6 March 2026 · filed 9 March 2026
- exercised options over 101,409 shares of NewAmsterdam Pharma CoSEC Form 49 March 2026Ordinary Shares · traded 9 March 2026 · filed 9 March 2026
- ▼ sold on the open market 101,409 shares of NewAmsterdam Pharma CoSEC Form 49 March 2026Ordinary Shares · traded 9 March 2026 · filed 9 March 2026
- exercised options over 101,409 shares of NewAmsterdam Pharma Co (a derivative holding)SEC Form 49 March 2026Option (right to buy) · traded 9 March 2026 · filed 9 March 2026
- ▼ sold on the open market 14,692 shares of NewAmsterdam Pharma CoSEC Form 424 February 2026Ordinary Shares · traded 20 February 2026 · filed 24 February 2026
- ▼ sold on the open market 30,789 shares of NewAmsterdam Pharma CoSEC Form 424 February 2026Ordinary Shares · traded 20 February 2026 · filed 24 February 2026
- ▼ sold on the open market 14,692 shares of NewAmsterdam Pharma CoSEC Form 424 February 2026Ordinary Shares · traded 20 February 2026 · filed 24 February 2026
- ▼ sold on the open market 30,789 shares of NewAmsterdam Pharma CoSEC Form 424 February 2026Ordinary Shares · traded 20 February 2026 · filed 24 February 2026
- ▼ sold on the open market 6,000 shares of NewAmsterdam Pharma CoSEC Form 47 January 2026Ordinary Shares · traded 5 January 2026 · filed 7 January 2026
- was granted 25,500 shares of NewAmsterdam Pharma CoSEC Form 47 January 2026Ordinary Shares · traded 7 January 2026 · filed 7 January 2026
- was granted 115,000 shares of NewAmsterdam Pharma Co (a derivative holding)SEC Form 47 January 2026Option (right to buy) · traded 7 January 2026 · filed 7 January 2026
- was granted 115,000 shares of NewAmsterdam Pharma Co (a derivative holding)SEC Form 47 January 2026Option (right to buy) · traded 7 January 2026 · filed 7 January 2026
- ▼ sold on the open market 6,000 shares of NewAmsterdam Pharma CoSEC Form 47 January 2026Ordinary Shares · traded 5 January 2026 · filed 7 January 2026
- was granted 25,500 shares of NewAmsterdam Pharma CoSEC Form 47 January 2026Ordinary Shares · traded 7 January 2026 · filed 7 January 2026
- ▼ sold on the open market 50,000 shares of NewAmsterdam Pharma CoSEC Form 425 August 2025Ordinary Shares · traded 21 August 2025 · filed 25 August 2025
- ▼ sold on the open market 42,342 shares of NewAmsterdam Pharma CoSEC Form 425 August 2025Ordinary Shares · traded 22 August 2025 · filed 25 August 2025
- ▼ sold on the open market 7,658 shares of NewAmsterdam Pharma CoSEC Form 425 August 2025Ordinary Shares · traded 22 August 2025 · filed 25 August 2025
- was granted 45,481 shares of NewAmsterdam Pharma Co (a derivative holding)SEC Form 428 March 2025Restricted Stock Unit · traded 26 March 2025 · filed 28 March 2025
- exercised options over 45,481 shares of NewAmsterdam Pharma Co (a derivative holding)SEC Form 428 March 2025Restricted Stock Unit · traded 26 March 2025 · filed 28 March 2025
- was granted 19,302 shares of NewAmsterdam Pharma CoSEC Form 428 March 2025Ordinary Shares · traded 26 March 2025 · filed 28 March 2025
- exercised options over 45,481 shares of NewAmsterdam Pharma CoSEC Form 428 March 2025Ordinary Shares · traded 26 March 2025 · filed 28 March 2025
- exercised options over 150,000 shares of NewAmsterdam Pharma Co (a derivative holding)SEC Form 426 March 2025Option (right to buy) · traded 24 March 2025 · filed 26 March 2025
- exercised options over 150,000 shares of NewAmsterdam Pharma CoSEC Form 426 March 2025Ordinary Shares · traded 24 March 2025 · filed 26 March 2025
- was granted 34,000 shares of NewAmsterdam Pharma CoSEC Form 47 January 2025Ordinary Shares · traded 7 January 2025 · filed 7 January 2025
- was granted 200,000 shares of NewAmsterdam Pharma Co (a derivative holding)SEC Form 46 January 2025Option (right to buy) · traded 2 January 2025 · filed 6 January 2025
- exercised options over 201,673 shares of NewAmsterdam Pharma Co (a derivative holding)SEC Form 427 March 2024Option (right to buy) · traded 26 March 2024 · filed 27 March 2024
- exercised options over 201,673 shares of NewAmsterdam Pharma CoSEC Form 427 March 2024Ordinary Shares · traded 26 March 2024 · filed 27 March 2024
- had shares withheld for tax on 11,197 shares of NewAmsterdam Pharma CoSEC Form 427 March 2024Ordinary Shares · traded 26 March 2024 · filed 27 March 2024
- ▼ sold on the open market 190,476 shares of NewAmsterdam Pharma CoSEC Form 427 March 2024Ordinary Shares · traded 26 March 2024 · filed 27 March 2024
- was granted 500,000 shares of NewAmsterdam Pharma Co (a derivative holding)SEC Form 43 January 2024Option (right to buy) · traded 1 January 2024 · filed 3 January 2024
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.